<DOC>
	<DOCNO>NCT01653470</DOCNO>
	<brief_summary>The purpose study identify safe tolerable dose BMS-906024 combination follow three chemotherapy regimen : Paclitaxel , 5FU plus Irinotecan ( FOLFIRI ) , Carboplatin plus Paclitaxel subject advance metastatic solid tumor</brief_summary>
	<brief_title>Study Evaluate Safety &amp; Tolerability BMS-906024 Combination With Chemotherapy &amp; Define DLTs &amp; MTD BMS-906024 Combination With One Following Chemotherapy Regimens ; Weekly Paclitaxel , 5FU+Irinotecan Carboplatin+Paclitaxel Subjects With Advanced / Metastatic Solid Tumors</brief_title>
	<detailed_description>DLTs = dose-limiting toxicity MTD = Maximum tolerate dose</detailed_description>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Camptothecin</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<criteria>For information regard BMS clinical trial participation , please visit www.BMSStudyConnect.com . Subjects advance metastatic solid tumor chemotherapy regimen consider appropriate Subjects nonsmall cell lung cancer triplenegative breast cancer prefer Biopsy accessible tumor ( may use archived tumor sample certain circumstance ) Life expectancy least 3 month Eastern Cooperative Oncology Group ( ECOG ) Performance Status 01 Measurable disease Uncontrolled brain metastasis Infection Gastrointestinal ( GI ) disease increase risk diarrhea ( e.g . inflammatory bowel disease ) Uncontrolled significant cardiovascular disease Subjects take medication know increase risk Torsades de Pointes</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2016</verification_date>
</DOC>